Saturday, April 5, 2014

Intercept Pharmaceuticals: Too Much Selling Going On

In what’s turned into a bad day for biotech stocks, Intercept Pharmaceuticals (ICPT) is among the worst performers.

REUTERS

Shares of Intercept Pharmaceuticals have dropped 8.3% to $295, lagging the 3.3% drop in the iShares Nasdaq Biotechnology ETF (IBB) and the 4.7% decline in the SPDR S&P Biotech ETF (XBI). Gilead Sciences (GILD) has fallen 2.1% to $72.44 and Amgen (AMGN) is off just 1.8% at $121.88.

Blame SAC’s decision to drastically cut its position and a secondary offering for Intercept’s decline.

Wedbush’s Liana Moussatos explains the purpose of the secondary offering:

Intercept raised approximately $183.3MM in a follow-on offering of 600,000 shares at $320/share. We project runway into Q3 2016 from Q3 2015, which covers major milestones, including regulatory review and potential approval of OCA in PBC in 2015…

Reiterate OUTPERFORM rating and acquisition value of $493. Our acquisition value is calculated by applying a 30% annual discount to our net peak WW revenues for each drug/indication and applying a 1-10x multiple depending on stage of development to reflect risk. Each combination is added in a sum-of-parts to calculate an acquisition value for [Intercept Pharmaceuticals] and projected to the end of 2015 to include the time frame we see for potential acquisition.

Just expect a heck of a lot of volatility before then.

No comments:

Post a Comment

.